Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Glioblastoma 100Glioma 42Brain Neoplasms 28Neuroblastoma 25Astrocytoma 18Gliosarcoma 15Sarcoma, Ewing 12Rhabdomyosarcoma 12Neoplasms 12Recurrence 11Medulloblastoma 11Small Cell Lung Carcinoma 8Sarcoma 8Oligodendroglioma 8Melanoma 7Osteosarcoma 6Ependymoma 6Diffuse Intrinsic Pontine Glioma 6Central Nervous System Neoplasms 4Rhabdoid Tumor 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Neoplasm Metastasis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Ganglioneuroblastoma 3Desmoplastic Small Round Cell Tumor 3Colorectal Neoplasms 3

Interventions

Temozolomide 2Capecitabine 2Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Etoposide 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Somatostatinoma × Temozolomide × 1 year × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡